NSC243928 induces cell death in
triple-negative breast cancer cells in a LY6K-dependent manner.
NSC243928 has been reported as an anti-
cancer agent in the NCI small molecule library. The molecular mechanism of
NSC243928 as an anti-
cancer agent in the treatment of
tumor growth in the syngeneic mouse model has not been established. With the success of
immunotherapies, novel anti-
cancer drugs that may elicit an anti-
tumor immune response are of high interest in the development of novel drugs to treat solid
cancer. Thus, we focused on studying whether
NSC243928 may elicit an anti-
tumor immune response in the in vivo mammary
tumor models of 4T1 and E0771. We observed that
NSC243928 induced immunogenic cell death in 4T1 and E0771 cells. Furthermore,
NSC243928 mounted an anti-
tumor immune response by increasing immune cells such as patrolling monocytes, NKT cells, B1 cells, and decreasing PMN MDSCs in vivo. Further studies are required to understand the exact mechanism of
NSC243928 action in inducing an anti-
tumor immune response in vivo, which can be used to determine a molecular signature associated with
NSC243928 efficacy.
NSC243928 may be a good target for future immuno-oncology
drug development for
breast cancer.